You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨利好疊加 康希諾AH股同步拉昇超7%
格隆匯 05-14 11:01
格隆匯5月14日丨康希諾生物-B(06185.HK)和康希諾(688185.SH)均大漲超7%,H股報336港元,A股報530元。Q1公司實現4.67億元收入,在新冠疫苗帶動下公司收入端實現大幅增長。中信建投指出,長期發展可期公司重磅產品MCV4 和MCV2 獲批在即,即將在2021年步入商業化階段。另外,目前公司天津廠區已正式投產,該行預計Q2在自產新冠疫苗帶動下有望迎來毛利率逐季提升。此外,公司新冠疫苗(5型腺病毒載體)已獲批上市,有望為公司貢獻鉅額利潤。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account